Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Yuguo LiuDépartement de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.
Svenja C SchülerDépartement de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.
Simon DumontierDépartement de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.
Frederic BalgDepartment of Surgery, Division of Orthopedics, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.ORCID http://orcid.org/0000-0002-3369-7364
Sonia BedardDepartment of Surgery, Division of Orthopedics, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.ORCID http://orcid.org/0000-0002-8100-5908
Thibaut DesgeorgesNestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.
Jerome N FeigeNestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.
Pierre-Luc BoudreaultDépartement de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.ORCID http://orcid.org/0000-0002-2032-7970
C Florian BentzingerDépartement de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada. cf.bentzinger@usherbrooke.ca.ORCID http://orcid.org/0000-0003-0422-9622
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) 505064275Fonds de Recherche du Québec - Nature et Technologies (Quebec Fund for Research in Nature and Technology) Dossier 331297Fonds de Recherche du Québec - Santé (Fonds de la recherche en sante du Quebec) 305231Fonds de Recherche du Québec - Santé (Fonds de la recherche en sante du Quebec) Dossiers 296357, 34813, and 36789Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) PJT-162442 and PJT-507167Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) PJT-480163Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada) RGPIN-2017-05490 and RTI-2025-00383Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada) RGPIN-2022-04028 and RTI-2020-00560
6 · The paper itself
Abstract
Loss of Fibronectin (FN) from the skeletal muscle stem cell (MuSC) niche represents a root cause of regenerative failure in aging. While FN has pleiotropic functions during healthy skeletal muscle regeneration, it remains unclear how aging affects its spatiotemporal specificity for MuSCs. Here, we demonstrate that activated MuSCs secrete an autoregulatory FN splice variant containing the EDB extra domain (EDB(+) FN), which is not expressed by accessory cells in the niche. EDB(+) FN splicing in MuSCs depends on serine/arginine-rich splicing factor 1 (Srsf1) whose promoter is controlled by Smad3. EDB(+) FN knockdown or downregulation in aging affects MuSC proliferation through aberrant integrin signaling and impairs skeletal muscle regeneration. During a defined regeneration interval in aged mice, Smad3 activation using transforming growth factor-beta 1 (TGFβ1) improves MuSC function and skeletal muscle repair by stimulating EDB(+) FN secretion. Altogether, we identify and characterize the TGFβ1-Smad3-Srsf1-EDB(+) FN pathway as a therapeutic target for age-associated regenerative failure.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
TGFβ-Smad3 signaling restores cell-autonomous Srsf1-mediated splicing of fibronectin in aged skeletal muscle stem cells. · full record | OpenQuestion